Kaleido Biosciences Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	no data
CEO ownership	n/a
Management average tenure	no data
Board average tenure	5.8yrs

Recent management updates

Are Insiders Buying Kaleido Biosciences, Inc. (NASDAQ:KLDO) Stock?

Dec 14

Recent updates

CEO

Kaleido Biosciences has no CEO, or we have no data on them.

Board Members

Name	Position	Tenure	Compensation	Ownership
Theodose Melas-Kyriazi	Independent Chairperson of the Board	5.3yrs	US$146.56k	no data
Laurie Glimcher	Member of Scientific Advisory Board	5.8yrs	no data	no data
C. Kahn	Member of Scientific Advisory Board	5.8yrs	no data	no data
Jean Mixer	Independent Director	5.1yrs	US$127.23k	no data
Anthony Quinn	Independent Director	8.8yrs	US$124.73k	no data
Laura Kiessling	Member of Scientific Advisory Board	5.8yrs	no data	no data
Anne Prener	Independent Director	4.6yrs	US$118.73k	no data
Fergus Shanahan	Chairman of Scientific Advisory Board	5.2yrs	no data	no data
Max Nieuwdorp	Member of Scientific Advisory Board	5.8yrs	no data	no data
Peter Turnbaugh	Member of Scientific Advisory Board	5.8yrs	no data	no data
Robert Jenq	Member of Scientific Advisory Board	5.8yrs	no data	no data

5.8yrs

Average Tenure

65yo

Average Age

Experienced Board: KLDO's board of directors are considered experienced (5.8 years average tenure).

Kaleido Biosciences Management

Management criteria checks 1/4

Key information

Recent management updates

Kaleido Biosciences, Inc. Announces Resignation of Katharine Knobil as Chief Medical Officer and Head of Research and Development, Effective as of January 29, 2021

Are Insiders Buying Kaleido Biosciences, Inc. (NASDAQ:KLDO) Stock?

Kaleido Biosciences, Inc. Announces Change of Role of Michael Bonney from Executive Chair of the Board to Chair of the Board

Kaleido Biosciences, Inc. Announces Management Changes, Effective October 13, 2020

Recent updates

Kaleido Biosciences, Inc. Announces Cessation of All of the Company’s Ongoing Operations

Kaleido Biosciences, Inc. announced delayed annual 10-K filing

Kaleido Biosciences, Inc. Decides Halt Work on a Planned Phase 2 Chronic Obstructive Pulmonary Disease (COPD) Study

Third quarter 2021 earnings released: US$0.54 loss per share (vs US$0.65 loss in 3Q 2020)

Price target increased to US$15.60

Price target decreased to US$14.33

Consensus forecasts updated

Consensus forecasts updated

Chairman of the Board Michael Bonney has left the company

Consensus forecasts updated

Price target increased to US$17.83

Consensus revenue estimates fall to US$547.0k

Kaleido Biosciences EPS misses by $0.01

Consultant has left the company

Revenue and earnings miss expectations

Is Kaleido Biosciences, Inc. (NASDAQ:KLDO) Popular Amongst Insiders?

Kaleido Biosciences, Inc. has completed a Follow-on Equity Offering in the amount of $60.375 million.

Kaleido Biosciences announces $50M proposed public offering

New 90-day high: US$14.21

Kaleido Biosciences, Inc. Announces Resignation of Katharine Knobil as Chief Medical Officer and Head of Research and Development, Effective as of January 29, 2021

Kaleido Biosciences, Inc. Announces Positive Interim Results of Controlled Study of KB109 in Patients with Mild-To-Moderate COVID-19

Kaleido Bio's KB109 shows benefit in COVID-19 study

New 90-day high: US$11.40

Kaleido Biosciences Announces Completion of Enrollment of 350 Subjects in Controlled Study of KB109 in the Treatment of Mild-to-Moderate COVID-19

Kaleido concludes enrollment in KB109 study in COVID-19

Price target raised to US$14.00

Are Insiders Buying Kaleido Biosciences, Inc. (NASDAQ:KLDO) Stock?

Analysts update estimates

Price target lowered to US$11.60

Earnings beat expectations

Analysts update estimates

Kaleido Biosciences, Inc. Announces Change of Role of Michael Bonney from Executive Chair of the Board to Chair of the Board

Kaleido Biosciences, Inc. Provides Update on KB109 Clinical Data Timeline

Kaleido Biosciences, Inc. Announces Management Changes, Effective October 13, 2020

Kaleido Biosciences Announces First Patient Dosed in Clinical Study of Microbiome Metabolic Therapy KB295 in Patients with Mild-to-Moderate Ulcerative Colitis

New 90-day low: US$5.09

New 90-day low - US$5.78

New 90-day high - US$8.52

CEO

Board Members

Average Tenure

Average Age